XSPRAY — Xspray Pharma publ AB Share News
0.000.00%
Last trade - 00:00- SEK509.25m
- SEK476.65m
Brief: Xspray Q2 Revenue SEK 0
Brief: Xspray Pharma Resolves On Rights Issue Of About SEK 130 Mln
Brief: Xspray Pharma Signs License Agreement With Handa Therapeutics
Brief: Xspray Pharma Completes PopPK Modeling For NDA Submission Of XS003
Brief: Xspray Pharma Reports On FDA Pre-Approval Inspection
Brief: Xspray Q1 Revenue SEK 0
Brief: Xspray Pharma Re-Submits FDA Application
Brief: Xspray Q4 Revenue SEK 0
Brief: XSpray Pharma Changes Timeline For Dasynoc FDA Application Sumbission
Brief: Xspray Pharma To Get About SEK 135 Mln From Rights Issue
Brief: Xspray Q3 Revenue SEK 0
Brief: Xspray Resolves On Rights Issue Of About SEK 135 Mln, Raises Loan Of SEK 100 Mln
Brief: XSpray Pharma Announces Positive FDA Meeting, Plans For Dasynoc NDA Resubmission
Brief: Xspray Pharma Announces Positive FDA Meeting, Plans For Dasynoc NDA Resubmission
Brief: Xspray Q2 Revenue SEK 0
Brief: Flerie Purchased Shares In Xspray Pharma For Approx. Sek 5.6 Mln
Brief: Xspray Pharma's XS003 Study Shows Matching Bioavailability To Tasigna At More Than A 50% Lower Dose
Brief: Xspray Q1 Revenue SEK 0
Brief: XSpray Pharma Raises SEK 100.3 Mln Through Warrants To6